Tonix Pharmaceuticals to Showcase Innovations at 2025 BIO International Convention
TL;DR
Tonix Pharmaceuticals' CEO presentation at BIO 2025 could spotlight TNX-102 SL's Fast Track designation, offering investors a glimpse into potential market advantages.
Tonix Pharmaceuticals plans to submit an NDA for TNX-102 SL this month, following two successful Phase 3 studies for fibromyalgia management.
Tonix Pharmaceuticals' work on TNX-102 SL and TNX-4200 aims to improve pain management and military medical readiness, enhancing quality of life and safety.
Discover how Tonix Pharmaceuticals is revolutionizing pain management and public health with TNX-102 SL and a $34 million DoD contract for antiviral development.
Found this article helpful?
Share it with your network and spread the knowledge!
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that its CEO, Seth Lederman, M.D., will present at the prestigious 2025 BIO International Convention in Boston. This presentation, scheduled for June 16 at 5:00 p.m. in Room 153B, underscores the company's commitment to addressing critical health challenges through innovative therapies.
The company is on the verge of submitting a New Drug Application to the U.S. Food and Drug Administration for TNX-102 SL, a promising treatment for fibromyalgia that has shown significant results in phase 3 studies. With Fast Track designation from the FDA, TNX-102 SL represents a potential breakthrough in pain management. Additionally, Tonix's contract with the U.S. Department of Defense to develop TNX-4200 highlights its role in enhancing medical readiness against biological threats.
Tonix's diverse portfolio, including treatments for CNS disorders, organ transplant rejection, and rare diseases, positions it as a leader in biopharmaceutical innovation. The upcoming presentation at the BIO International Convention offers a platform to share these advancements with the global health community, signaling important progress in treating complex conditions and improving patient outcomes.
Curated from InvestorBrandNetwork (IBN)
